What are you looking for?

Need help finding what you are looking for? Contact Us

Compare

Free Samples

Home Market Research Reports Medical Device

PUBLISHER: QYResearch | PRODUCT CODE: 1432290

PUBLISHER: QYResearch | PRODUCT CODE: 1432290

Radioimmunotherapy- Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030

PUBLISHED: February 26, 2024

PAGES: 154 Pages

DELIVERY TIME: 2-3 business days

ADD TO COMPARE

SELECT AN OPTION

The global market for Radioimmunotherapy was estimated to be worth US$ 1865 million in 2023 and is forecast to a readjusted size of US$ 5408 million by 2030 with a CAGR of 14.63% during the forecast period 2024-2030.

North American market for Radioimmunotherapy was valued at $ 1100 million in 2023 and will reach $ 3274 million by 2030, at a CAGR of 14.13% during the forecast period of 2024 through 2030.

Asia-Pacific market for Radioimmunotherapy was valued at $ 171.72 million in 2023 and will reach $ 534.7 million by 2030, at a CAGR of 18.84% during the forecast period of 2024 through 2030.

Europe market for Radioimmunotherapy was valued at $ 574.41 million in 2023 and will reach $ 1581.23 million by 2030, at a CAGR of 14.48% during the forecast period of 2024 through 2030.

The global key companies of Radioimmunotherapy include Bayer, Novartis, Lantheus, Aurobindo Pharma, Mundipharma, China Isotope & Radiation, Curium Pharmaceuticals, etc. In 2023, the global five largest players hold a share approximately 99.45% in terms of revenue.

This report aims to provide a comprehensive presentation of the global market for Radioimmunotherapy, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Radioimmunotherapy by region & country, by Type, and by Application.

The Radioimmunotherapy market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Radioimmunotherapy.

Market Segmentation

By Company

Bayer
Novartis
Lantheus
Aurobindo Pharma
Mundipharma
China Isotope & Radiation
Curium Pharmaceuticals
Gilead Sciences
Clarity Pharmaceuticals
Curasight
Nordic Nanovector
Philogen
RadioMedix
Telix Pharmaceuticals
Orano Med
Actinium Pharmaceuticals
Y-mAbs Therapeutics
Fusion Pharmaceuticals

Segment by Type

Beta-emitting
Targeted Alpha Therapy

Segment by Application

Solid Tumor
Non Hodgkin Lymphoma

By Region

North America
United States
Canada
Mexico
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Other
Europe
Germany
France
U.K.
Italy
Russia
Rest of Europe
South America
Brazil
Rest of South America
Middle East & Africa
Middle East
Africa

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 2: Detailed analysis of Radioimmunotherapy company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 5: Revenue of Radioimmunotherapy in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 6: Revenue of Radioimmunotherapy in country level. It provides sigmate data by Type, and by Application for each country/region.

Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.

Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 9: Conclusion.

1 Market Overview

1.1 Radioimmunotherapy Product Introduction
1.2 Global Radioimmunotherapy Market Size Forecast (2019-2030)
1.3 Radioimmunotherapy Market Trends & Drivers
- 1.3.1 Radioimmunotherapy Industry Trends
- 1.3.2 Radioimmunotherapy Market Drivers & Opportunity
- 1.3.3 Radioimmunotherapy Market Challenges
- 1.3.4 Radioimmunotherapy Market Restraints
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered

2 Competitive Analysis by Company

2.1 Global Radioimmunotherapy Players Revenue Ranking (2023)
2.2 Global Radioimmunotherapy Revenue by Company (2019-2024)
2.3 Key Companies Radioimmunotherapy Area Served and Headquarters
2.4 Key Companies Radioimmunotherapy Product Offered
2.5 Global Key Players of Radioimmunotherapy, Date of Enter into This Industry
2.6 Radioimmunotherapy Market Competitive Analysis
- 2.6.1 Radioimmunotherapy Market Concentration Rate (2019-2024)
- 2.6.2 Global 5 Largest Companies by Radioimmunotherapy Revenue in 2023
- 2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Radioimmunotherapy as of 2023)
2.7 Mergers & Acquisitions, Expansion

3 Segmentation by Type

3.1 Introduction by Type
- 3.1.1 Beta-emitting
- 3.1.2 Targeted Alpha Therapy
3.2 Global Radioimmunotherapy Sales Value by Type
- 3.2.1 Global Radioimmunotherapy Sales Value by Type (2019 VS 2023 VS 2030)
- 3.2.2 Global Radioimmunotherapy Sales Value, by Type (2019-2030)
- 3.2.3 Global Radioimmunotherapy Sales Value, by Type (%) (2019-2030)

4 Segmentation by Application

4.1 Introduction by Application
- 4.1.1 Solid Tumor
- 4.1.2 Non Hodgkin Lymphoma
4.2 Global Radioimmunotherapy Sales Value by Application
- 4.2.1 Global Radioimmunotherapy Sales Value by Application (2019 VS 2023 VS 2030)
- 4.2.2 Global Radioimmunotherapy Sales Value, by Application (2019-2030)
- 4.2.3 Global Radioimmunotherapy Sales Value, by Application (%) (2019-2030)

5 Segmentation by Region

5.1 Global Radioimmunotherapy Sales Value by Region
- 5.1.1 Global Radioimmunotherapy Sales Value by Region: 2019 VS 2023 VS 2030
- 5.1.2 Global Radioimmunotherapy Sales Value by Region (2019-2024)
- 5.1.3 Global Radioimmunotherapy Sales Value by Region (2025-2030)
- 5.1.4 Global Radioimmunotherapy Sales Value by Region (%), (2019-2030)
5.2 North America
- 5.2.1 North America Radioimmunotherapy Sales Value, 2019-2030
- 5.2.2 North America Radioimmunotherapy Sales Value by Country (%), 2023 VS 2030
5.3 Europe
- 5.3.1 Europe Radioimmunotherapy Sales Value, 2019-2030
- 5.3.2 Europe Radioimmunotherapy Sales Value by Country (%), 2023 VS 2030
5.4 Asia Pacific
- 5.4.1 Asia Pacific Radioimmunotherapy Sales Value, 2019-2030
- 5.4.2 Asia Pacific Radioimmunotherapy Sales Value by Region (%), 2023 VS 2030
5.5 South America
- 5.5.1 South America Radioimmunotherapy Sales Value, 2019-2030
- 5.5.2 South America Radioimmunotherapy Sales Value by Country (%), 2023 VS 2030
5.6 Middle East & Africa
- 5.6.1 Middle East & Africa Radioimmunotherapy Sales Value, 2019-2030
- 5.6.2 Middle East & Africa Radioimmunotherapy Sales Value by Country (%), 2023 VS 2030

6 Segmentation by Key Countries/Regions

6.1 Key Countries/Regions Radioimmunotherapy Sales Value Growth Trends, 2019 VS 2023 VS 2030
6.2 Key Countries/Regions Radioimmunotherapy Sales Value, 2019-2030
6.3 North America
- 6.3.1 North America Radioimmunotherapy Sales Value, 2019-2030
- 6.3.2 North America Radioimmunotherapy Sales Value by Type (%), 2023 VS 2030
- 6.3.3 North America Radioimmunotherapy Sales Value by Application, 2023 VS 2030
6.4 Europe
- 6.4.1 Europe Radioimmunotherapy Sales Value, 2019-2030
- 6.4.2 Europe Radioimmunotherapy Sales Value by Type (%), 2023 VS 2030
- 6.4.3 Europe Radioimmunotherapy Sales Value by Application, 2023 VS 2030
6.5 Asia Pacific
- 6.5.1 Asia Pacific Radioimmunotherapy Sales Value, 2019-2030
- 6.5.2 Asia Pacific Radioimmunotherapy Sales Value by Type (%), 2023 VS 2030
- 6.5.3 Asia Pacific Radioimmunotherapy Sales Value by Application, 2023 VS 2030
6.6 South America
- 6.6.1 South America Radioimmunotherapy Sales Value, 2019-2030
- 6.6.2 South America Radioimmunotherapy Sales Value by Type (%), 2023 VS 2030
- 6.6.3 South America Radioimmunotherapy Sales Value by Application, 2023 VS 2030
6.7 Middle East and Africa
- 6.7.1 Middle East and Africa Radioimmunotherapy Sales Value, 2019-2030
- 6.7.2 Middle East and Africa Radioimmunotherapy Sales Value by Type (%), 2023 VS 2030
- 6.7.3 Middle East and Africa Radioimmunotherapy Sales Value by Application, 2023 VS 2030

7 Company Profiles

7.1 Bayer
- 7.1.1 Bayer Company Details
- 7.1.2 Bayer Business Overview
- 7.1.3 Bayer Radioimmunotherapy Products and Services
- 7.1.4 Bayer Revenue in Radioimmunotherapy Business (2019-2024)
- 7.1.5 Bayer Radioimmunotherapy SWOT Analysis
- 7.1.6 Bayer Business Strategy
7.2 Novartis
- 7.2.1 Novartis Company Details
- 7.2.2 Novartis Business Overview
- 7.2.3 Novartis Radioimmunotherapy Products and Services
- 7.2.4 Novartis Revenue in Radioimmunotherapy Business (2019-2024)
- 7.2.5 Novartis Radioimmunotherapy SWOT Analysis
- 7.2.6 Novartis Business Strategy
7.3 Lantheus
- 7.3.1 Lantheus Company Details
- 7.3.2 Lantheus Business Overview
- 7.3.3 Lantheus Radioimmunotherapy Products and Services
- 7.3.4 Lantheus Revenue in Radioimmunotherapy Business (2019-2024)
- 7.3.5 Lantheus Radioimmunotherapy SWOT Analysis
- 7.3.6 Lantheus Business Strategy
7.4 Aurobindo Pharma
- 7.4.1 Aurobindo Pharma Company Details
- 7.4.2 Aurobindo Pharma Business Overview
- 7.4.3 Aurobindo Pharma Radioimmunotherapy Products and Services
- 7.4.4 Aurobindo Pharma Revenue in Radioimmunotherapy Business (2019-2024)
- 7.4.5 Aurobindo Pharma Radioimmunotherapy SWOT Analysis
- 7.4.6 Aurobindo Pharma Business Strategy
7.5 Mundipharma
- 7.5.1 Mundipharma Company Details
- 7.5.2 Mundipharma Business Overview
- 7.5.3 Mundipharma Radioimmunotherapy Products and Services
- 7.5.4 Mundipharma Revenue in Radioimmunotherapy Business (2019-2024)
- 7.5.5 Mundipharma Business Strategy
7.6 China Isotope & Radiation
- 7.6.1 China Isotope & Radiation Company Details
- 7.6.2 China Isotope & Radiation Business Overview
- 7.6.3 China Isotope & Radiation Radioimmunotherapy Products and Services
- 7.6.4 China Isotope & Radiation Revenue in Radioimmunotherapy Business (2019-2024)
- 7.6.5 China Isotope & Radiation Radioimmunotherapy SWOT Analysis
- 7.6.6 China Isotope & Radiation Business Strategy
7.7 Curium Pharmaceuticals
- 7.7.1 Curium Pharmaceuticals Company Details
- 7.7.2 Curium Pharmaceuticals Business Overview
- 7.7.3 Curium Pharmaceuticals Radioimmunotherapy Products and Services
- 7.7.4 Curium Pharmaceuticals Revenue in Radioimmunotherapy Business (2019-2024)
- 7.7.5 Curium Pharmaceuticals Radioimmunotherapy SWOT Analysis
- 7.7.6 Curium Pharmaceuticals Business Strategy
7.8 Gilead Sciences
- 7.8.1 Gilead Sciences Company Details
- 7.8.2 Gilead Sciences Business Overview
- 7.8.3 Gilead Sciences Radioimmunotherapy Products and Services
- 7.8.4 Gilead Sciences Business Strategy
7.9 Clarity Pharmaceuticals
- 7.9.1 Clarity Pharmaceuticals Company Details
- 7.9.2 Clarity Pharmaceuticals Business Overview
- 7.9.3 Clarity Pharmaceuticals Radioimmunotherapy Products and Services
- 7.9.4 Clarity Pharmaceuticals Radioimmunotherapy SWOT Analysis
- 7.9.5 Clarity Pharmaceuticals Business Strategy
7.10 Curasight
- 7.10.1 Curasight Company Details
- 7.10.2 Curasight Business Overview
- 7.10.3 Curasight Radioimmunotherapy Products and Services
- 7.10.4 Curasight Radioimmunotherapy SWOT Analysis
- 7.10.5 Curasight Business Strategy
7.11 Nordic Nanovector
- 7.11.1 Nordic Nanovector Company Details
- 7.11.2 Nordic Nanovector Business Overview
- 7.11.3 Nordic Nanovector Radioimmunotherapy Products and Services
- 7.11.4 Nordic Nanovector Radioimmunotherapy SWOT Analysis
- 7.11.5 Nordic Nanovector Business Strategy
7.12 Philogen
- 7.12.1 Philogen Company Details
- 7.12.2 Philogen Business Overview
- 7.12.3 Philogen Radioimmunotherapy Products and Services
- 7.12.4 Philogen Radioimmunotherapy SWOT Analysis
- 7.12.5 Philogen Business Strategy
7.13 RadioMedix
- 7.13.1 RadioMedix Company Details
- 7.13.2 RadioMedix Business Overview
- 7.13.3 RadioMedix Radioimmunotherapy Products and Services
- 7.13.4 RadioMedix Business Strategy
7.14 Telix Pharmaceuticals
- 7.14.1 Telix Pharmaceuticals Company Details
- 7.14.2 Telix Pharmaceuticals Business Overview
- 7.14.3 Telix Pharmaceuticals Radioimmunotherapy Products and Services
- 7.14.4 Telix Pharmaceuticals Radioimmunotherapy SWOT Analysis
- 7.14.5 Telix Pharmaceuticals Business Strategy
7.15 Orano Med
- 7.15.1 Orano Med Company Details
- 7.15.2 Orano Med Business Overview
- 7.15.3 Orano Med Radioimmunotherapy Products and Services
- 7.15.4 Orano Med Radioimmunotherapy SWOT Analysis
- 7.15.5 Orano Med Business Strategy
7.16 Actinium Pharmaceuticals
- 7.16.1 Actinium Pharmaceuticals Company Details
- 7.16.2 Actinium Pharmaceuticals Business Overview
- 7.16.3 Actinium Pharmaceuticals Radioimmunotherapy Products and Services
- 7.16.4 Actinium Pharmaceuticals Radioimmunotherapy SWOT Analysis
- 7.16.5 Actinium Pharmaceuticals Business Strategy
7.17 Y-mAbs Therapeutics
- 7.17.1 Y-mAbs Therapeutics Company Details
- 7.17.2 Y-mAbs Therapeutics Business Overview
- 7.17.3 Y-mAbs Therapeutics Radioimmunotherapy Products and Services
- 7.17.4 Y-mAbs Therapeutics Business Strategy
7.18 Fusion Pharmaceuticals
- 7.18.1 Fusion Pharmaceuticals Company Details
- 7.18.2 Fusion Pharmaceuticals Business Overview
- 7.18.3 Fusion Pharmaceuticals Radioimmunotherapy Products and Services
- 7.18.4 Fusion Pharmaceuticals Business Strategy

8 Industry Chain Analysis

8.1 Radioimmunotherapy Industrial Chain
8.2 Radioimmunotherapy Upstream Analysis
- 8.2.1 Key Raw Materials
- 8.2.2 Raw Materials Key Suppliers
- 8.2.3 Manufacturing Cost Structure
8.3 Midstream Analysis
8.4 Downstream Analysis (Customers Analysis)
8.5 Sales Model and Sales Channels
- 8.5.1 Radioimmunotherapy Sales Model
- 8.5.2 Sales Channel
- 8.5.3 Radioimmunotherapy Distributors

9 Research Findings and Conclusion

10 Appendix

10.1 Research Methodology
- 10.1.1 Methodology/Research Approach
- 10.1.2 Data Source
10.2 Author Details
10.3 Disclaimer

List of Tables

Table 1. Radioimmunotherapy Market Trends
Table 2. Radioimmunotherapy Market Drivers & Opportunity
Table 3. Radioimmunotherapy Market Challenges
Table 4. Radioimmunotherapy Market Restraints
Table 5. Global Radioimmunotherapy Revenue by Company (2019-2024) & (US$ Million)
Table 6. Global Radioimmunotherapy Revenue Market Share by Company (2019-2024)
Table 7. Key Companies Radioimmunotherapy Area Served and Headquarters
Table 8. Key Companies Radioimmunotherapy Product Type
Table 9. Key Companies Time to Begin Mass Production of Radioimmunotherapy
Table 10. Global Radioimmunotherapy Companies Market Concentration Ratio (CR5 and HHI)
Table 11. Global Top Companies Market Share by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Radioimmunotherapy as of 2023)
Table 12. Mergers & Acquisitions, Expansion Plans
Table 13. Key Players of Ibritumomab
Table 14. Key Players of Apamistamab
Table 15. Key Players of Lilotomab
Table 16. Key Players of Omburtamab
Table 17. Global Radioimmunotherapy Sales Value by Type: 2019 VS 2023 VS 2030 (US$ Million)
Table 18. Global Radioimmunotherapy Sales Value by Type (2019-2024) & (US$ Million)
Table 19. Global Radioimmunotherapy Sales Value by Type (2025-2030) & (US$ Million)
Table 20. Global Radioimmunotherapy Sales Market Share in Value by Type (2019-2024)
Table 21. Global Radioimmunotherapy Sales Market Share in Value by Type (2025-2030)
Table 22. Global Radioimmunotherapy Sales Value by Application: 2019 VS 2023 VS 2030 (US$ Million)
Table 23. Global Radioimmunotherapy Sales Value by Application (2019-2024) & (US$ Million)
Table 24. Global Radioimmunotherapy Sales Value by Application (2025-2030) & (US$ Million)
Table 25. Global Radioimmunotherapy Sales Market Share in Value by Application (2019-2024)
Table 26. Global Radioimmunotherapy Sales Market Share in Value by Application (2025-2030)
Table 27. Global Radioimmunotherapy Sales Value by Region, (2019 VS 2023 VS 2030) & (US$ Million)
Table 28. Global Radioimmunotherapy Sales Value by Region (2019-2024) & (US$ Million)
Table 29. Global Radioimmunotherapy Sales Value by Region (2025-2030) & (US$ Million)
Table 30. Global Radioimmunotherapy Sales Value by Region (2019-2024) & (%)
Table 31. Global Radioimmunotherapy Sales Value by Region (2025-2030) & (%)
Table 32. Key Countries/Regions Radioimmunotherapy Sales Value Growth Trends, (US$ Million): 2019 VS 2023 VS 2030
Table 33. Key Countries/Regions Radioimmunotherapy Sales Value, (2019-2024) & (US$ Million)
Table 34. Key Countries/Regions Radioimmunotherapy Sales Value, (2025-2030) & (US$ Million)
Table 35. Bayer Company Details
Table 36. Bayer Business Overview
Table 37. Bayer Radioimmunotherapy Products and Services
Table 38. Bayer Revenue in Radioimmunotherapy Business (2019-2024) & (US$ Million)
Table 39. Bayer Radioimmunotherapy SWOT Analysis
Table 40. Bayer Business Strategy
Table 41. Novartis Company Details
Table 42. Novartis Business Overview
Table 43. Novartis Radioimmunotherapy Products and Services
Table 44. Novartis Revenue in Radioimmunotherapy Business (2019-2024) & (US$ Million)
Table 45. Novartis Radioimmunotherapy SWOT Analysis
Table 46. Novartis Business Strategy
Table 47. Lantheus Company Details
Table 48. Lantheus Business Overview
Table 49. Lantheus Radioimmunotherapy Products and Services
Table 50. Lantheus Revenue in Radioimmunotherapy Business (2019-2024) & (US$ Million)
Table 51. Lantheus Radioimmunotherapy SWOT Analysis
Table 52. Lantheus Business Strategy
Table 53. Aurobindo Pharma Company Details
Table 54. Aurobindo Pharma Business Overview
Table 55. Aurobindo Pharma Radioimmunotherapy Products and Services
Table 56. Aurobindo Pharma Revenue in Radioimmunotherapy Business (2019-2024) & (US$ Million)
Table 57. Aurobindo Pharma Radioimmunotherapy SWOT Analysis
Table 58. Aurobindo Pharma Business Strategy
Table 59. Mundipharma Company Details
Table 60. Mundipharma Business Overview
Table 61. Mundipharma Radioimmunotherapy Products and Services
Table 62. Mundipharma Revenue in Radioimmunotherapy Business (2019-2024) & (US$ Million)
Table 63. Mundipharma Business Strategy
Table 64. China Isotope & Radiation Company Details
Table 65. China Isotope & Radiation Business Overview
Table 66. China Isotope & Radiation Radioimmunotherapy Products and Services
Table 67. China Isotope & Radiation Revenue in Radioimmunotherapy Business (2019-2024) & (US$ Million)
Table 68. China Isotope & Radiation Radioimmunotherapy SWOT Analysis
Table 69. China Isotope & Radiation Business Strategy
Table 70. Curium Pharmaceuticals Company Details
Table 71. Curium Pharmaceuticals Business Overview
Table 72. Curium Pharmaceuticals Radioimmunotherapy Products and Services
Table 73. Curium Pharmaceuticals Revenue in Radioimmunotherapy Business (2019-2024) & (US$ Million)
Table 74. Curium Pharmaceuticals Radioimmunotherapy SWOT Analysis
Table 75. Curium Pharmaceuticals Business Strategy
Table 76. Gilead Sciences Company Details
Table 77. Gilead Sciences Business Overview
Table 78. Gilead Sciences Radioimmunotherapy Products and Services
Table 79. Gilead Sciences Business Strategy
Table 80. Clarity Pharmaceuticals Company Details
Table 81. Clarity Pharmaceuticals Business Overview
Table 82. Clarity Pharmaceuticals Radioimmunotherapy Products and Services
Table 83. Clarity Pharmaceuticals Radioimmunotherapy SWOT Analysis
Table 84. Clarity Pharmaceuticals Business Strategy
Table 85. Curasight Company Details
Table 86. Curasight Business Overview
Table 87. Curasight Radioimmunotherapy Products and Services
Table 88. Curasight Radioimmunotherapy SWOT Analysis
Table 89. Curasight Business Strategy
Table 90. Nordic Nanovector Company Details
Table 91. Nordic Nanovector Business Overview
Table 92. Nordic Nanovector Radioimmunotherapy Products and Services
Table 93. Nordic Nanovector Radioimmunotherapy SWOT Analysis
Table 94. Nordic Nanovector Business Strategy
Table 95. Philogen Company Details
Table 96. Philogen Business Overview
Table 97. Philogen Radioimmunotherapy Products and Services
Table 98. Philogen Radioimmunotherapy SWOT Analysis
Table 99. Philogen Business Strategy
Table 100. RadioMedix Company Details
Table 101. RadioMedix Business Overview
Table 102. RadioMedix Radioimmunotherapy Products and Services
Table 103. RadioMedix Business Strategy
Table 104. Telix Pharmaceuticals Company Details
Table 105. Telix Pharmaceuticals Business Overview
Table 106. Telix Pharmaceuticals Radioimmunotherapy Products and Services
Table 107. Telix Pharmaceuticals Radioimmunotherapy SWOT Analysis
Table 108. Telix Pharmaceuticals Business Strategy
Table 109. Orano Med Company Details
Table 110. Orano Med Business Overview
Table 111. Orano Med Radioimmunotherapy Products and Services
Table 112. Orano Med Radioimmunotherapy SWOT Analysis
Table 113. Orano Med Business Strategy
Table 114. Actinium Pharmaceuticals Company Details
Table 115. Actinium Pharmaceuticals Business Overview
Table 116. Actinium Pharmaceuticals Radioimmunotherapy Products and Services
Table 117. Actinium Pharmaceuticals Radioimmunotherapy SWOT Analysis
Table 118. Actinium Pharmaceuticals Business Strategy
Table 119. Y-mAbs Therapeutics Company Details
Table 120. Y-mAbs Therapeutics Business Overview
Table 121. Y-mAbs Therapeutics Radioimmunotherapy Products and Services
Table 122. Y-mAbs Therapeutics Business Strategy
Table 123. Fusion Pharmaceuticals Company Details
Table 124. Fusion Pharmaceuticals Business Overview
Table 125. Fusion Pharmaceuticals Radioimmunotherapy Products and Services
Table 126. Fusion Pharmaceuticals Business Strategy
Table 127. Key Raw Materials Lists
Table 128. Raw Materials Key Suppliers Lists
Table 129. Radioimmunotherapy Manufacturing Cost Structure
Table 130. Radioimmunotherapy Downstream Customers
Table 131. Radioimmunotherapy Distributors List
Table 132. Research Programs/Design for This Report
Table 133. Key Data Information from Secondary Sources
Table 134. Key Data Information from Primary Sources

List of Figures

Figure 1. Radioimmunotherapy Product Picture
Figure 2. Global Radioimmunotherapy Sales Value, 2019 VS 2023 VS 2030 (US$ Million)
Figure 3. Global Radioimmunotherapy Sales Value (2019-2030) & (US$ Million)
Figure 4. Radioimmunotherapy Report Years Considered
Figure 5. Global Radioimmunotherapy Players Revenue Ranking (2023) & (US$ Million)
Figure 6. The 5 Largest Companies in the World: Market Share by Radioimmunotherapy Revenue in 2023
Figure 7. Ibritumomab Features
Figure 8. Tositumomab Features
Figure 9. Targeted Alpha Therapy Picture
Figure 10. Global Radioimmunotherapy Sales Value by Type (2019 VS 2023 VS 2030) & (US$ Million)
Figure 11. Global Radioimmunotherapy Sales Value Market Share by Type, 2023
Figure 12. Global Radioimmunotherapy Sales Value Market Share by Type, 2030
Figure 13. Prostate Cancer
Figure 14. Product Picture of Non Hodgkin Lymphoma
Figure 15. Global Radioimmunotherapy Sales Value by Application (2019 VS 2023 VS 2030) & (US$ Million)
Figure 16. Global Radioimmunotherapy Sales Value Market Share by Application, 2023
Figure 17. Global Radioimmunotherapy Sales Value Market Share by Application, 2030
Figure 18. Global Radioimmunotherapy Sales Market Share in Value by Application (2025-2030)
Figure 19. North America Radioimmunotherapy Sales Value (2019-2030) & (US$ Million)
Figure 20. North America Radioimmunotherapy Sales Value by Country (%), 2023 VS 2030
Figure 21. Europe Radioimmunotherapy Sales Value, (2019-2030) & (US$ Million)
Figure 22. Europe Radioimmunotherapy Sales Value by Country (%), 2023 VS 2030
Figure 23. Asia Pacific Radioimmunotherapy Sales Value, (2019-2030) & (US$ Million)
Figure 24. Asia Pacific Radioimmunotherapy Sales Value by Region (%), 2023
Figure 25. Asia Pacific Radioimmunotherapy Sales Value by Region (%), 2030
Figure 26. South America Radioimmunotherapy Sales Value, (2019-2030) & (US$ Million)
Figure 27. South America Radioimmunotherapy Sales Value by Country (%), 2023
Figure 28. South America Radioimmunotherapy Sales Value by Country (%), 2030
Figure 29. Middle East & Africa Radioimmunotherapy Sales Value, (2019-2030) & (US$ Million)
Figure 30. Middle East & Africa Radioimmunotherapy Sales Value by Country (%), 2023
Figure 31. Middle East & Africa Radioimmunotherapy Sales Value by Country (%), 2030
Figure 32. Key Countries/Regions Radioimmunotherapy Sales Value (%), (2019-2030)
Figure 33. North America Radioimmunotherapy Sales Value, (2019-2030) & (US$ Million)
Figure 34. North America Radioimmunotherapy Sales Value by Type (%), 2023 VS 2030
Figure 35. North America Radioimmunotherapy Sales Value by Application (%), 2023 VS 2030
Figure 36. Europe Radioimmunotherapy Sales Value, (2019-2030) & (US$ Million)
Figure 37. Europe Radioimmunotherapy Sales Value by Type (%), 2023 VS 2030
Figure 38. Europe Radioimmunotherapy Sales Value by Application (%), 2023 VS 2030
Figure 39. Asia Pacific Radioimmunotherapy Sales Value, (2019-2030) & (US$ Million)
Figure 40. Asia Pacific Radioimmunotherapy Sales Value by Type (%), 2023 VS 2030
Figure 41. Asia Pacific Radioimmunotherapy Sales Value by Application (%), 2023 VS 2030
Figure 42. South America Radioimmunotherapy Sales Value, (2019-2030) & (US$ Million)
Figure 43. South America Radioimmunotherapy Sales Value by Type (%), 2023 VS 2030
Figure 44. South America Radioimmunotherapy Sales Value by Application (%), 2023 VS 2030
Figure 45. Middle East and Africa Radioimmunotherapy Sales Value, (2019-2030) & (US$ Million)
Figure 46. Middle East and Africa Radioimmunotherapy Sales Value by Type (%), 2023 VS 2030
Figure 47. Middle East and Africa Radioimmunotherapy Sales Value by Application (%), 2023 VS 2030
Figure 48. Bayer Revenue Growth Rate in Radioimmunotherapy Business (2019-2024)
Figure 49. Novartis Revenue Growth Rate in Radioimmunotherapy Business (2019-2024)
Figure 50. Lantheus Revenue Growth Rate in Radioimmunotherapy Business (2019-2024)
Figure 51. Aurobindo Pharma Revenue Growth Rate in Radioimmunotherapy Business (2019-2024)
Figure 52. Mundipharma Revenue Growth Rate in Radioimmunotherapy Business (2019-2024)
Figure 53. China Isotope & Radiation Revenue Growth Rate in Radioimmunotherapy Business (2019-2024)
Figure 54. Curium Pharmaceuticals Revenue Growth Rate in Radioimmunotherapy Business (2019-2024)
Figure 55. Radioimmunotherapy Industrial Chain
Figure 56. Channels of Distribution
Figure 57. Bottom-up and Top-down Approaches for This Report
Figure 58. Data Triangulation
Figure 59. Key Executives Interviewed